Advanced Visualization and Analysis Suite for Spectral CT Receives FDA Clearance

An advanced clinical applications suite for spectral Computed Tomography (CT) has received US Food and Drug Administration (FDA) 510(k) clearance for the US.

The suite of advanced visualization and analysis tools was designed to give clinicians on-demand spectral information, and clinical decision support to analyze incidental findings, without the need for additional scans and additional radiation exposure for the patient.

The Spectral Diagnostic Suite (SpDS) was designed by Royal Philips (Amsterdam, the Netherlands) for the Philips IQon Spectral CT scanner. The SpDS includes Spectral enhanced Comprehensive Cardiac Analysis (sCCA), Spectral enhanced Advanced Vessel Analysis (sAVA), Spectral enhanced Tumor Tracking (sTT), and enables clinicians to view and analyze spectral datasets in a reading room, on a Picture Archiving and Communication Systems (PACS), or remotely. The Philips Spectral suite also enables clinicians to perform segmentation, on different energy levels, advanced fusion, and more detailed comparison of images.

Mikael Strindlund, senior vice president & general manager of CT at Philips, said, "The game-changing capabilities of the Spectral Diagnostic Suite represent our ongoing commitment to drive advanced innovation in medical imaging to improve clinical output and diagnostic confidence, leading to better care for patients at lower dose exposure. Providing clinicians with additional data to help support the right clinical decisions while improving workflow and patient experience, is at the core of everything we do."

Related Links:
Philips Healthcare